Search - tctmd.com

Displaying 1 - 20 of 34

Sort: Relevancy | Date

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

News Conference News TCT 2024

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

Michael O'Riordan

November 06, 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

November 01, 2024

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

News Conference News TCT 2024

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

October 30, 2024

EVOLVED: Early AVR Fails to Help Asymptomatic AS Patients With Fibrosis

News Conference News TCT 2024

EVOLVED: Early AVR Fails to Help Asymptomatic AS Patients With Fibrosis

Michael O'Riordan

October 28, 2024

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

News Conference News TCT 2024

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

October 28, 2024

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

News Conference News TCT 2023

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

October 27, 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

News Conference News TCT 2023

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

October 24, 2023

SURTAVI: Five-Year Results From a Randomized Trial of TAVR vs. SAVR in Patients at Intermediate Surgical Risk

Presentation TCT 2021

SURTAVI: Five-Year Results From a Randomized Trial of TAVR vs. SAVR in Patients at Intermediate Surgical Risk

Presenter: Nicolas Van Mieghem

November 05, 2021

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

News Conference News TCT 2021

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

November 05, 2021

Acurate Neo Still Falls Short of Sapien 3 in SCOPE 1-Year Follow-up

News Conference News TCT 2020

Acurate Neo Still Falls Short of Sapien 3 in SCOPE 1-Year Follow-up

Michael O'Riordan

October 23, 2020

MitraBridge: Could a MitraClip Help Patients Avoid Heart Transplant?

News Conference News TCT 2020

MitraBridge: Could a MitraClip Help Patients Avoid Heart Transplant?

October 16, 2020

Sapien 3 Stroke Rate Perplexes in 1-Year SOLVE-TAVI Results

News Conference News TCT 2020

Sapien 3 Stroke Rate Perplexes in 1-Year SOLVE-TAVI Results

Michael O'Riordan

October 16, 2020

Large Databases Hint at Sentinel Benefit During TAVR, but Uncertainty Remains

News Conference News TCT 2020

Large Databases Hint at Sentinel Benefit During TAVR, but Uncertainty Remains

October 16, 2020

MITHRAS: No Upside to Closing iASDs Caused by Transcatheter MV Interventions

News Conference News TCT 2020

MITHRAS: No Upside to Closing iASDs Caused by Transcatheter MV Interventions

October 15, 2020

Acurate Neo Fails to Match Results of CoreValve Evolut: SCOPE 2

News Conference News TCT 2020

Acurate Neo Fails to Match Results of CoreValve Evolut: SCOPE 2

Michael O'Riordan

October 15, 2020

Efficacy Eludes TriGUARD 3 Cerebral Protection Device: REFLECT II

News Conference News TCT 2020

Efficacy Eludes TriGUARD 3 Cerebral Protection Device: REFLECT II

October 15, 2020

MitraClip Pricey but ‘Acceptable’ in COAPT Cost-Efficacy Analysis

News Conference News TCT 2019

MitraClip Pricey but ‘Acceptable’ in COAPT Cost-Efficacy Analysis

September 29, 2019

Long-term PARTNER 2A Results Put Spotlight on Paravalvular Leak in TAVR

News Conference News TCT 2019

Long-term PARTNER 2A Results Put Spotlight on Paravalvular Leak in TAVR

September 29, 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

News Conference News TCT 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Michael O'Riordan

September 28, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.